Breezhaler®

DEVICE2 trials

Sponsors

Almirall, S.A., Novartis Pharmaceuticals

Conditions

Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic Obstructive (COPD)

Phase 3

Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD

CompletedNCT01915784

Almirall, S.A.Chronic Obstructive Pulmonary Disease (COPD)

Start: 2013-07-31End: 2013-10-31Updated: 2015-05-29

Phase 4

Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices

CompletedNCT02596009

Novartis PharmaceuticalsPulmonary Disease, Chronic Obstructive (COPD)

Start: 2015-12-16End: 2016-04-29Updated: 2018-06-26

Related Papers

Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.

2018-06-1440 citations